RxDoctor Payments Data

Jose Weisinger, MD

Nephrology · North Miami Beach, FLNPI 1891965778

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 59.4% of the total. That places this record below the midpoint for nephrology clinicians in FL, where the typical reported total is $1,407.

$220in general payments, 2019–2025

Across 11 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$131
  • Mallinckrodt Hospital Products Inc.$32
  • La Jolla Pharmaceutical Company$23
  • Mallinckrodt Enterprises LLC$18
  • AstraZeneca$16
$53,610in research payments, 2019–2025

Across 27 payments — averaging $1985.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$54K

What the payments were for

  • Food & beverage$21799%
  • Education$31%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$220 in reported general payments places this provider in the 15th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida →

Medicare billing

Part B allowed, 2024
$9,628
Medicare patients
40
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol55$58,247
LinzessLinaclotide14$7,421
Verapamil ErVerapamil Hcl16$629
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide16$612
Tamsulosin Hcl11$238
Metoprolol Succinate12$157
Allopurinol13$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$16$58,24755 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 756 nephrology providers in Florida.

Other nephrology in North Miami Beach

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →